(NASDAQ: ZBIO) Zenas Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 47.81%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.86%.
Zenas Biopharma's earnings in 2025 is -$177,006,000.On average, 8 Wall Street analysts forecast ZBIO's earnings for 2025 to be -$163,400,648, with the lowest ZBIO earnings forecast at -$202,007,382, and the highest ZBIO earnings forecast at -$109,655,255. On average, 8 Wall Street analysts forecast ZBIO's earnings for 2026 to be -$202,870,644, with the lowest ZBIO earnings forecast at -$243,481,830, and the highest ZBIO earnings forecast at -$152,102,451.
In 2027, ZBIO is forecast to generate -$177,558,135 in earnings, with the lowest earnings forecast at -$193,669,541 and the highest earnings forecast at -$124,688,637.